To achieve the best outcome in cancer therapy, a combination of small molecules targeting both epigenetic pathways and the UPS may be ideal to maintain the optimal levels of RUNX3 to sustain its tumor suppressor function. This evidence concerns the gene RUNX3 and neoplasm.